EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

February 9, 2018: By Jon Swedien

EyeGate Pharmaceuticals’ EGP-437 outperformed the vehicle in its Phase IIb study, but the product candidate for post-cataract pain and inflammation failed to meet the study’s co-primary endpoints.

The vehicle group’s response was better than anticipated, EyeGate said.

The double-masked, randomized, vehicle-controlled Phase IIb study enrolled 106 subjects at seven US clinical sites and evaluated the safety and efficacy of transscleral iontophoretically delivered EGP-437, dexamethasone, through the company’s EyeGate II Delivery System.

Patients in the study had undergone cataract surgery and been implanted with a monofocal posterior chamber IOL. They received treatment beginning immediately after surgery.

The study’s primary endpoints were:

–Proportion of subjects with an anterior chamber cell count of zero at day seven;

–Proportion of subjects with a pain score of zero at day one.

EGP-437 demonstrated a higher rate of success compared with vehicle at all time points, but the difference between its scores and the placebo’s scores did not demonstrate statistical significance, EyeGate said.

EyeGate will continue evaluating EGP-437 for post-ocular surgery pain and inflammation, said Barbara Wirostko, MD, the company’s chief medical officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023